Leslie A. Fecher

TL;DR: The ability of circulating tumor DNA (ctDNA) to detect tumors in 640 patients with various cancer types was evaluated and suggested that ctDNA is a broadly applicable, sensitive, and specific biomarker that can be used for a variety of clinical and research purposes.

TL;DR: The outcomes of a cohort of patients with cancer and COVID-19 are characterised and potential prognostic factors for mortality and severe illness are identified and race and ethnicity, obesity status, cancer type, type of anticancer therapy, and recent surgery were not associated with mortality.

TL;DR: The data show substantial clinical activity of trametinib in melanoma and suggest that MEK is a valid therapeutic target, and differences in response rates according to mutations indicate the importance of mutational analyses in the future.

TL;DR: The recommended phase 2 dose of 2 mg trametinib once a day is tolerable, with manageable side-effects, and its inhibition of the expected target and clinical activity warrants its further development as a monotherapy and in combination.

TL;DR: The response rate for the selective, allosteric MEK1/MEK2 inhibitor trametinib (GSK1120212), in patients with metastatic BRAF-mutant melanoma, and minimal clinical activity was observed as sequential therapy in patients previously treated with a BRAF inhibitor suggest that BRAf-inhibitor resistance mechanisms likely confer resistance to MEK- inhibitor monotherapy.